Volixibat Hits Primary Endpoint in PSC Trial, NDA Path Opens

Mirum Pharmaceuticals has cleared a critical clinical threshold in its VISTAS study, reporting that volixibat met its primary endpoint in patients with primary sclerosing cholangitis (PSC). For regulatory affairs and manufacturing teams, a positive Phase trial readout in a rare cholestatic disease with no currently approved pharmacological treatment signals that NDA preparation and process validation timelines are likely accelerating.

PSC represents a significant unmet need in hepatology. The condition, characterised by progressive biliary inflammation and fibrosis, has historically offered patients few options beyond liver transplantation. Volixibat, an ileal bile acid transporter (IBAT) inhibitor, targets bile acid reabsorption -- a mechanism Mirum has previously advanced in cholestatic liver diseases including PFIC and Alagille syndrome. That prior regulatory experience with the same molecular entity will inform, but not simplify, the CMC and clinical data package required for a PSC-specific submission.

Manufacturing and regulatory considerations now move to the foreground. Scale-up readiness, process performance qualification under 21 CFR Part 211, and alignment with ICH Q10 pharmaceutical quality system expectations will be central to any pre-NDA meeting with FDA. Given volixibat's existing approval history in other indications, Mirum's teams will need to assess whether current commercial manufacturing infrastructure supports the projected PSC patient population, and whether any formulation or dosing differences in the VISTAS study introduce new comparability requirements.

Sterility assurance and supply chain continuity will also warrant scrutiny during regulatory review, particularly as rare disease designations can accelerate review timelines and compress the window available for post-approval manufacturing supplements. QA directors should note that any changes to the established drug product process since prior approvals will require documented bridging data.

Source: Mirum Pharmaceuticals, Inc. announcement via EIN Presswire, published 4 May 2026. Pharma Now has reported solely on information contained in the company's public statement. No independent clinical or manufacturing data has been verified.